The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance ...

The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is MSD's biggest-selling drug – bringing in more than $15 billion in the first ...